Quantitative structure activity relationship studies of diaryl thiophen derivatives as selective COX-2 inhibitors

Pharmazie

Volumn 60, Issue 4, 2005, Pages 254-258

  Shahapurkar, S ^a   Kawathekar, N ^b   Chaturvedi, S C ^a,c  

^a Devi Ahilya Vishwavidyalaya   (India)

^b SHRI G S INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^c DEVI AHILYA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; THIOPHENE DERIVATIVE;

ANALYSIS OF VARIANCE; ARTICLE; DRUG STRUCTURE; ENZYME INHIBITION; HYDROPHOBICITY; PHARMACOPHORE; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CHEMISTRY, PHYSICAL; COMPUTATIONAL BIOLOGY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 17644388125     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Chavatte P, Yous S, Marot C, Baurin N, Lesieur D (2001) Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis. J Med Chem 44: 3223-3230.
2. Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewew WE, Ackerman NR (1990) Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254: 180-187.
3. Herchman HR (1996) Prostaglandin synthase-2 Biochem. Biophys Acta 1299: 125-140.
4. Hinz B, Brune K (2002) Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 300: 367-375.
5. Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P (1997) Cyclo-oxygenase isoenzymes. How recent findings affect thinking about non-steroidal anti-inflammatory drugs Drugs. 53: 563-582.
6. Kargman S, O'Neil GP, Vickers PJ, Evans JF, Mancini JA, Jothy S (1995) Expression of prostaglandinG/H synthase-1 and -2 in human colon cancer. Cancer Res 55: 2556-2559.
7. Kurumbail RG, Stevens AM, Gierse JK, Mc Donald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents Nature 384: 644-648.
8. Penning TD, Talley JJ, Carter SR, Collins PW, Doctor S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogrs RS, Rogiers D, Yu SS, Anderson GD, Burton EG, Cogbum JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veehuizen AW, Zhang YY, Isakson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib) J Med Chem 40: 347-357
9. Pinto DJP, Copeland RA, Covington MB, Pitts WJ, Batt DG, Orwat MJ, Lam GN, Joshi A, Charn YC, Wang S, Trzaskos JM, Magolda RL, Kornhauser DM (1996) Chemistry and pharmacokinetics of diaryl thiophens and terphenyls as selective Cox-2 inhibitor. Bioorg Med Chem Lett 24: 2907-2912.
10. Prasit P, Riendeau D (1997) Selective cyclooxygenase-2 inhibitors. Annu Rep Med Chem 32: 211-220.
11. Prasit P, Wang Z, Brideau C, Chan C, Gauthier JY, Gordon R, Charleson S, Cromlish WA, Ethier D, Evans JF, Ford-Hutchinson AW, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Leger J, Mancini J, O'Neill GP, Quellet M, Percival MD, Perrier H, Riendeau D, Rodger D, Tagari P, Therien P, Vickers P, Wong E, Xu L, Young RN, Zamboni R, (1999) The discovery of rofecoxib, [MK 966, VIOXX, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone] an orally active cyclooxygenase-2 inhibitor. Bioorg Med Chem Lett 9: 1773-1778.
12. 2 synthase-1 Nature 367: 243-249.
13. Vane J, Botting RM (1995) New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44: 1-10.